The DOXY-PEP Study

Sexually transmitted infection (STI) risk in high risk patients is a common problem compounded by antimicrobial resistance. Join host, Geoff Wall, with guest Amanda Bushman, as they discuss a new post-exposure prophylaxis (PEP) therapy for STI prevention The GameChangerSexually transmitted infection incidence is higher than most clinicians suspect. Doxycycline may offer effective post-exposure prophylaxis for some HIV positive patients.HostGeoff Wall, PharmD, BCPS, FCCP, BCGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint Health GuestAmanda Bushman, PharmD, BCIDPClinical PharmacistUnityPoint Health References Luetkemeyer AF, Donnell D, Dombrowski JC, et al. Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections. N Engl J Med. 2023 Apr 6;388(14):1296-1306. doi: 10.1056/NEJMoa2211934. PMID: 37018493; PMCID: PMC10140182. Pharmacist Members, REDEEM YOUR CPE HERE!Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode) CE Information Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Discuss the DOXY-PEP study2. Apply results of DOXY-PEP to patient care 0.05 CEU/0.5 HrUAN: 0107-0000-23-205-H01-PInitial release date: 5/22/2023Expiration date: 5/22/2024Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram